- Home
- VSNT vs PTGX Comparison
VSNT vs PTGX Comparison
Compare VSNT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSNT | PTGX |
|---|---|---|
| Founded | 2025 | 2006 |
| Country | United States | United States |
| Employees | 4400 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | VSNT | PTGX |
|---|---|---|
| Price | $40.05 | $110.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $43.67 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.7M | 507.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $3.83 | $2,195.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.17 | $49.86 |
| 52 Week High | $45.58 | $111.45 |
Technical Indicators
Market Signals| Indicator | VSNT | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 61.85 |
| Support Level | $38.91 | $94.48 |
| Resistance Level | $43.02 | N/A |
| Average True Range (ATR) | 1.22 | 4.80 |
| MACD | -0.35 | 1.33 |
| Stochastic Oscillator | 18.18 | 90.91 |
Price Performance
Historical ComparisonAbout VSNT Versant Media Group Inc. Class A Common Stock
Versant Media Group Inc is an independent media company comprised of NBCUniversal's cable television networks, including USA Network, CNBC, MSNBC, Oxygen, SYFY, and Golf Channel, along with complementary digital assets Fandango, Rotten Tomatoes, GolfNow, GolfPass, and SportsEngine.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.